First, we review some early evidence of antibody response following COVID vaccination in patients with multiple myeloma and CLL.
Then, we discuss nivolumab's approval with chemo for first-line treatment of gastric cancer (& GEJ & adenocarcinoma of the esophagus) and the MANHATTAN study and its high rate of MRD-negativity in myeloma.
5-yr OS data is published for pembrolizumab in PD-L1 > 50% NSCLC and a new drug is approved for the 1st time while recording the Pod.
